Skip to main content

Table 2 Impact of current AECB episode on daily life activities and sleep disturbance (efficacy population)

From: Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)

Parameter

Days with impact on daily life activities

Nights with sleep disturbance

(N = 2292)

(N = 1740)

 

n (%)

Mean

SD

n (%)

Mean

SD

Gender

      

Male

1308 (57.1)

6.6

5.3

971 (55.8)

4.1

3.8

Female

984 (42.9)

6.6

5.8

769 (44.2)

4.1

3.6

Missing

0 (0)

-

-

0 (0)

-

-

Age group (years)

 

≥ 35 to < 50

615 (26.8)

6.4

5.2

406 (23.3)

3.7

2.7

≥ 50 to < 65

922 (40.2)

6.7

5.9

712 (40.9)

4.0

4.1

≥ 65 to < 80

680 (29.7)

6.7

5.3

557 (32.0)

4.5

3.8

≥ 80

71 (3.1)

5.8

3.9

63 (3.6)

4.3

3.0

Missing

4 (0.2)

11.8

5.2

2 (0.1)

4.0

1.4

Smoking status

 

Never

1027 (44.8)

6.7

5.6

786 (45.2)

4.0

3.7

Past or current smoker

1255 (54.8)

6.5

5.4

945 (54.3)

4.2

3.7

Missing

10 (0.4)

8.7

5.3

9 (0.5)

3.6

2.1

Concomitant diseases of special interest

      

COPD

1549 (67.6)

6.6

5.6

1216 (69.9)

4.3

3.9

Asthma

389 (17.0)

7.5

6.8

331 (19.0)

4.4

3.5

Emphysema

568 (24.8)

7.7

6.4

461 (26.5)

4.5

3.7

Bronchiectasis

151 (6.6)

7.3

6.9

128 (7.4)

4.6

4.7

Cor pulmonale

251 (11.0)

8.1

6.4

222 (12.8)

5.1

4.2

Cardiomyopathy

146 (6.4)

7.9

7.4

122 (7.0)

5.4

5.0

Cardiac ischemia

544 (23.7)

7.2

6.3

429 (24.7)

4.2

3.5

Heart insufficiency

135 (5.9)

10.9

10.1

126 (7.2)

6.4

6.3

Cardiac arrhythmia

145 (6.3)

7.7

5.1

131 (7.5)

4.9

4.0

Chronic alcoholism

39 (1.7)

6.0

6.8

24 (1.4)

5.3

5.5

Diabetes

238 (10.4)

6.3

5.3

196 (11.3)

4.1

3.2

No diseases of special interest

324 (14.1)

5.8

4.1

203 (11.7)

3.0

2.8

Anthonisen grade

Type I

1014 (44.2)

7.1

5.1

793 (45.6)

4.5

3.8

Type II

913 (39.8)

6.5

5.9

666 (38.3)

3.8

3.6

Type III

353 (15.4)

5.6

5.6

274 (15.7)

3.6

3.3

Missing

12 (0.5)

7.4

6.2

7 (0.4)

7.3

7.5

Number of severe symptoms per patient at start of therapy

 

1

446 (19.5)

6.0

5.2

295 (17.0)

3.5

3.5

2

596 (26.0)

6.0

5.0

417 (24.0)

3.5

3.3

3

377 (16.4)

6.3

5.0

279 (16.0)

4.1

3.1

4

241 (10.5)

6.8

5.4

193 (11.1)

4.4

3.9

5

163 (7.1)

7.7

4.9

142 (8.2)

4.9

3.4

6

142 (6.2)

10.2

7.9

141 (8.1)

5.8

3.7

7

66 (2.9)

9.6

7.5

66 (3.8)

6.2

5.8

8

16 (0.7)

10.4

9.6

15 (0.9)

8.1

8.6

None

245 (10.7)

5.6

4.6

192 (11.0)

3.2

3.1

  1. AECB, acute exacerbation of chronic bronchitis; COPD, chronic obstructive pulmonary disease.